- Cello, the healthcare focused strategic marketing group, posts gross profits of £41.9m for the six months to the end of June - up 6.1% on last time.

Revenue fell to £77.0m (2014: £78.3m) and headline operating profit was £4.4m (2014: £4.7m). Headline operating margins were 10.5% (2014: 12.0%). Headline pre-tax profit was £4.2m (2014: £4.4m). The interim dividend has been increased 5% to 0.84p (2014: 0.80p).

Chief executive Mark Scott said: "Cello's emergence as a global provider of advisory services to the pharmaceutical and biotech industry is progressing at a rapid pace, with continuing strong growth from our core healthcare business, most notably in the US where our primary investments are being made. Cello Signal's strong digital and social media expertise will prove an invaluable addition to the group's capabilities in the healthcare space and represents a key source of future organic growth."

At 8:18am: [LON:CLL] Cello Group PLC share price was -4.5p at 88.5p

Story provided by